You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
麗珠集團(000513.SZ):7009.1萬元投資新元素醫藥獲7.8215%的股權
格隆匯 01-17 17:43

格隆匯1月17日丨麗珠集團(000513.SZ)公佈,2020117日,公司附屬公司珠海市麗珠醫藥股權投資管理有限公司(“麗珠股權投資公司”)江蘇新元素醫藥科技有限公司(“新元素醫藥”)、史東方(SHI DONGFANG“創始股東”)常州同信股權投資企業(有限合夥)(“常州同信”)常州鑫氏創業投資合夥企業(有限合夥)(“常州鑫氏”,與史東方及常州同信統稱“原始股東”)廈門金圓凱泰展鴻健康成長創業投資合夥企業(有限合夥)(“廈門金圓,與麗珠股權投資公司統稱“投資者”)簽訂了關於江蘇新元素醫藥科技有限公司增資協議

根據增資協議,麗珠股權投資公司將出資人民幣7009.1萬元認購新元素醫藥增註冊資本人民幣225.0639萬元,佔增資完成後新元素醫藥註冊資本的7.8215%

江蘇新元素醫藥科技有限公司(中外合資)創辦於2012年,以自主研發、全球市場為主,開發具有全球商業價值和全球競爭力的1.1類創新藥,管線包括痛風、NASH等代謝類疾病及腫瘤類疾病。公司核心團隊人員主要來自美國,具有廣泛的創新藥物研發經驗。公司CEO史東方博士回國前的20年,在美一直從事抗腫瘤、抗HCV和治療二型糖尿病等First-in-Cla創新藥的研發。

增資完成後,公司根據增資協議相關規定與新元素醫藥就治療代謝病和腫瘤的創新藥物等相關產品開展合作此次投資符合公司中長期研發管線的戰略佈局

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account